Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol ...Middle East

TARRYTOWN, N.Y., May 21, 2022 /PRNewswire/ -- Children already on other lipid-lowering therapies entered the trial with dangerously high LDL-C (264 mg/dL on average), and 79% saw their LDL-C reduced by at least half at 24 weeks FDA submission planned by end of 2022 Regeneron...

Hence then, the article about evkeeza evinacumab phase 3 trial demonstrates 48 ldl c reduction in children with ultra rare form of high cholesterol was published today ( Saturday 21/05/2022 - 02:30 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol )

Also on site :

• The Iran War Hits Your Pocket
• Trump receives yet another prize while addressing Republican fundraiser with rambling speech blasting Democrats
• Videos show wave of missiles fired from Lebanon to Israel